https://www.thebodypro.com/article/last-word-aplaviroc-ccr-5-antagonist-poor-efficacy
HIV Treatments in DevelopmentConference Coverage

The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy

    Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.